Bayesian methods for analysis of biosimilar phase III trials

DOI10.1002/SIM.7814MaRDI QIDQ7022187zbMATH OpenFDO

Authors Robert E. Weiss, Xiaomao Xia, Nan Zhang, Eric C. Chi, Hui Wang

Publication date 25 February 2025

Published in Statistics in Medicine (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/SIM.7814

zbMATH Keywords

clinical trialsfrequentist-Bayes comparisoninformative priormeta-analysisprior specification

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials
• A New Perspective on Priors for Generalized Linear Models
• Assessing biosimilarity and interchangeability of biosimilar products
• Bioequivalence trials, intersection-union tests and equivalence confidence sets. With comments and a rejoinder by the authors
• Combining Historical and Randomized Controls for Assessing Trends in Proportions
• Experimental design for drug development: a bayesian approach
• scientific article; zbMATH DE number 4155731 (Why is no real title available?)
• scientific article; zbMATH DE number 946667 (Why is no real title available?)
• Locally Optimal Designs for Estimating Parameters
• Optimal Bayesian design applied to logistic regression experiments

This page was built for publication: Bayesian methods for analysis of biosimilar phase III trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q7022187)